|
| PF-06446846 HYDROCHLORIDE Basic information |
Product Name: | PF-06446846 HYDROCHLORIDE | Synonyms: | PF-06446846 HYDROCHLORIDE;N-(3-chloropyridin-2-yl)-N-[(3R)-piperidin-3-yl]-4-(3H-[1,2,3]triazolo[4,5-b]pyridin-3-yl)benzamide hydrochloride;PF 6446846 hydrochloride;PF-06446846 hydrochloride >=98% (HPLC);PF06446846 hydrochloride,PF 06446846 hydrochloride;(R)-4-(3H-[1,2,3]Triazolo[4,5-b]pyridin-3-yl)-N-(3-chloropyridin-2-yl)-N-(piperidin-3-yl)benzamide xhydrochloride | CAS: | 1632250-50-0 | MF: | C22H21Cl2N7O | MW: | 470.36 | EINECS: | | Product Categories: | | Mol File: | 1632250-50-0.mol | |
| PF-06446846 HYDROCHLORIDE Chemical Properties |
storage temp. | room temp | solubility | DMSO : 250 mg/mL (531.52 mM) | form | powder | color | white to beige | optical activity | [α]/D -60 to -50°, c = 1 in methanol |
| PF-06446846 HYDROCHLORIDE Usage And Synthesis |
Biological Activity | PF-06446846 hydrochloride is an orally active, highly selective translation inhibitor of the proprotein convertase subtilisin/kexin type 9 (PCSK9). It inhibits PCSK9 by inducing ribosome parking around codon 34. | in vitro | PF-06446846 inhibits the secretion of PCSK9 by Huh7 cells with an IC 50 of 0.3 μM. | in vivo | PF-06446846 (oral gavage; 5-50 mg/kg/day for 14 days) lowers plasma PCSK9 in a dose-dependent manner and lowers total cholesterol levels. Animal Model: | Male Sprague-Dawley (Crl:CD [SD] rats, 6-8 wk old at initiation of dosing) | Dosage: | 5, 15, and 50 mg/kg | Administration: | Oral gavage; daily for 14 days | Result: | Lowered plasma PCSK9 in a dose-dependent manner and lowered total cholesterol levels. | | target | |
| PF-06446846 HYDROCHLORIDE Preparation Products And Raw materials |
|